Table 1.
Patients characteristics (N = 62).
| Characteristics | EBRT (N) | NBT+EBRT (N) | p value |
|---|---|---|---|
| Sex | 0.758 | ||
| Male | 18 | 17 | |
| Female | 13 | 14 | |
| Age (years) | 1.095 | ||
| ≤ 50 | 16 | 14 | |
| > 50 | 15 | 17 | |
| Location of tumor | 0.936 | ||
| Upper | 12 | 14 | |
| Middle | 16 | 12 | |
| Lower | 3 | 5 | |
| Initial length | 0.625 | ||
| ≤ 5 cm | 18 | 17 | |
| > 5 cm | 13 | 14 | |
| Pathological grade | 0.085 | ||
| I | 5 | 7 | |
| II | 20 | 19 | |
| III | 6 | 5 | |
| Initial clinical stage | 0.785 | ||
| II | 14 | 12 | |
| III | 17 | 19 | |
| Initial ECOG-PS | 0.634 | ||
| 0–1 | 20 | 19 | |
| 2 | 11 | 12 | |
| 3 | 0 | 0 | |
| Initial radiation dose(GY) | 0.082 | ||
| ≥ 60 Gy | 28 | 29 | |
| < 60 Gy | 3 | 2 | |
| RFS | 0.093 | ||
| ≥ 12 months | 19 | 20 | |
| < 12 months | 12 | 11 |
EBRT external beam radiotherapy, ECOG-PS Eastern Cooperative Oncology Group performance status, NBT neutron intraluminal brachytherapy, RFS recurrence-free survival.